CHICAGO, June 3 /PRNewswire/ -- VasSol's introduction of NOVA(R) Renal, a gadolinium-free procedure, offers a safe alternative to the standard contrast-enhanced Magnetic Resonance Angiography (MRA) and Magnetic Resonance Imaging (MRI) scans for patients suffering from renal disease. Contrast enhanced renal MRA/MRI has traditionally required the injection of a gadolinium based agent which the FDA has linked to the occurrence of a potentially life-threatening disease, Nephrogenic Systemic Fibrosis (NSF). NOVA(R) Renal provides a comprehensive evaluation of the renal arteries without contrast or ionizing radiation.
Who's at Risk?
According to a report by the Centers for Disease Control (CDC), one in six individuals have kidney disease, threatening their renal function and putting them at greater risk when receiving a gadolinium-enhanced MRI scan.
About NOVA(R)
NOVA(R) is the first commercially available technology to measure actual blood flow rates in individual vessels using MRA/MRI scanners. The technology provides 3-D visualization of blood vessels, as well as quantitative blood flow measurements. NOVA(R) adds a new element to the traditional MRA/MRI scan by merging hemodynamic assessment with anatomic images. Non-invasive blood flow measurements with NOVA(R) provide clinicians with more information for the diagnosis and treatment of vascular disease.
About VasSol
VasSol, is founded on 12 years of multidisciplinary research and clinical work conducted at the University of Illinois at Chicago. Bringing together experts in the fields of circulatory fluid dynamics and computer modeling, VasSol developed NOVA(R), a vascular analysis technology, which helps answer the fundamental questions healthcare professionals confront when treating vascular disease: what is the severity, how is the condition best treated and what is the outcome? The VasSol mission is to shape the future of medicine by applying leading computer, engineering and medical technologies to the diagnosis, treatment and prevention of vascular disease. Further information can be found by visiting http://www.vassolinc.com
SOURCE VasSol
